Financial Performance - Operating revenue for the third quarter was RMB 18,017,185 thousand, a decrease of 1.08% compared to the same period last year[3] - Net profit attributable to shareholders was RMB 609,412 thousand, down 37.82% year-on-year[3] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 514,998 thousand, a decrease of 38.70% compared to the previous year[3] - Basic and diluted earnings per share were both RMB 0.375, reflecting a decline of 37.82% year-on-year[3] - The weighted average return on equity was 1.70%, a decrease of 1.17 percentage points compared to the same period last year[3] - Total operating revenue for the first three quarters of 2024 reached RMB 59.06 billion, a slight increase of 1.5% compared to RMB 58.18 billion in the same period of 2023[20] - Total operating costs increased to RMB 55.41 billion, up 3.0% from RMB 53.78 billion year-over-year[20] - Net profit for the first three quarters of 2024 was RMB 3.29 billion, a decrease of 16.3% from RMB 3.93 billion in the same period of 2023[21] - Basic and diluted earnings per share for the first three quarters of 2024 were both RMB 1.943, down from RMB 2.332 in the same period of 2023[22] - The total comprehensive income for the first three quarters of 2024 was RMB 3.29 billion, a decrease from RMB 3.92 billion in the same period of 2023[22] Assets and Liabilities - Total assets at the end of the reporting period were RMB 79,255,540 thousand, an increase of 0.85% from the end of the previous year[3] - Current liabilities reached RMB 36,260,578,892.35, showing a slight increase from RMB 36,235,290,500.95 in the previous period[16] - Total liabilities decreased to RMB 41,202,453,235.03 from RMB 41,909,053,857.29, indicating a reduction of approximately 1.7%[17] - The company's total assets as of September 30, 2024, were RMB 79,255,540,499.70, compared to RMB 78,586,877,764.09 at the end of 2023, reflecting a growth of 0.9%[18] - Cash and cash equivalents decreased to RMB 17,187,621,128.03 from RMB 21,308,844,204.44, a decline of 19.5%[14] - Accounts receivable increased to RMB 16,682,453,602.94, up from RMB 15,112,494,798.69, representing an increase of 10.4%[14] - The company’s long-term borrowings decreased to RMB 2,645,148,946.45 from RMB 3,323,717,917.22, a reduction of 19.5%[17] - The total equity attributable to shareholders was RMB 38,053,087,264.67, an increase from RMB 36,677,823,906.80, indicating a growth of 3.7%[19] Cash Flow - Cash flow from operating activities showed a net outflow of RMB 751,362 thousand, a significant increase of 183.33% compared to the previous year[3] - Cash flow from operating activities amounted to RMB 55.02 billion, an increase from RMB 53.47 billion year-over-year[23] - The net cash flow from operating activities for the first three quarters of 2024 was (RMB 751,362,230.20), a decline from RMB 901,626,427.54 in 2023[24] - Cash inflow from financing activities in the first three quarters of 2024 was RMB 8,534,366,363.04, down from RMB 10,798,825,985.69 in 2023, representing a decrease of about 21%[26] - The net cash flow from financing activities improved to RMB 587,309,332.49 in 2024, compared to a negative cash flow of (RMB 916,775,454.39) in 2023[26] - The total cash outflow for investment activities in the first three quarters of 2024 was RMB 4,239,805,542.16, compared to RMB 2,209,174,427.17 in 2023, indicating a significant increase in investment outflows[25] - The company received cash from investment activities totaling RMB 4,938,146,046.98 in 2024, compared to RMB 4,569,762,461.76 in 2023, showing an increase of about 8%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,322[8] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., holds 732,305,103 shares, representing 45.04% of the total shares[9] - HKSCC Nominees Limited, the second-largest shareholder, holds 219,787,142 shares, accounting for 13.52%[9] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 62%[9] - Guangzhou Pharmaceutical Group Co., Ltd. has no restricted shares, indicating full liquidity of its holdings[11] - The company has not reported any significant changes in the shareholding structure due to margin trading activities[12] Operational Insights - The decrease in net profit was primarily due to macroeconomic fluctuations, market competition, and industry policies affecting subsidiary sales revenue[7] - There are no other important reminders regarding the company's operational situation during the reporting period[13] - The company has not provided any audited financial statements for the quarter[13] Tax and Expenses - The company reported a decrease in tax expenses to RMB 716.60 million from RMB 823.71 million in the previous year, reflecting a 12.9% reduction[21] - The company reported a decrease in tax payments, with RMB 2,251,415,772.94 in 2024 compared to RMB 2,415,414,380.29 in 2023, indicating a reduction of approximately 6.8%[24] - Research and development expenses remained stable at RMB 578.51 million, slightly down from RMB 579.48 million in the previous year[20] - The company recorded an increase in investment income to RMB 191.40 million, down from RMB 257.94 million year-over-year[20] - Other comprehensive income after tax for the first three quarters of 2024 was RMB 5.45 million, compared to a loss of RMB 6.77 million in the same period of 2023[21]
白云山(00874) - 2024 Q3 - 季度业绩